Stephen C. Glover

PDS Biotechnology Corp ZyVersa Therapeutics, Inc.Ambrx Biopharma Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 1 buy · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€24k

▼ Sales (0 ops.)

—

Latest filing published 03 Mar 2025 for PDS Biotechnology Corp, €24k. Read the official filing

Filing timeline

BuySale

Stephen C. Glover

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

PDS Biotechnology Corp 1 purchase · last 03 Mar 2025

Since each purchase

PDS Biotechnology Corp
Filed 03 Mar 2025 · 594 days ago · €24k
-45.7%
Entry US$1.29 · Close at T+365 US$0.70

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Stephen C. Glover: trading record in brief

Stephen C. Glover is a declared insider at 3 companies; the most frequent names are Ambrx Biopharma Inc., PDS Biotechnology Corp and ZyVersa Therapeutics, Inc. We count 3 filings; the first trade dates from 12 December 2022 and the latest from 28 February 2025.

The open-market record is one-sided, with 1 purchase worth €24k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 share grants. In 2025 alone, the filings show 1 purchase and no sales.

On 3 March 2025 came the latest disclosure, an open-market purchase for €24k in PDS Biotechnology Corp. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.